CSL Ltd (ASX: CSL)
The first Australian stock that could be one of the best to buy now according to the broker is biotechnology company CSL.
Bell Potter believes that the key CSL Behring business will return to form this year and then drive strong earnings growth in the coming years. It explains:
We expect CSL will achieve guidance of "annual double-digit earnings growth" over the mid-term driven largely by the legacy plasma business, Behring, particularly its immunoglobulin sales. While CSL's Seqirus and Vifor business units do face near-term headwinds (reduced flu market demand and generic iron competition), these two units combined only contribute less than a third of total earnings.
The broker has a buy rating and $345.00 price target on the company's shares. Based on its current share price of $272.00, this implies potential upside of 27% for investors over the next 12 months.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$240.08 |
Change
0.790(0.33%) |
Mkt cap ! $116.3B | |||
| Open | High | Low | Value | Volume |
| $239.46 | $243.99 | $238.91 | $67.04M | 278.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8 | $240.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $240.12 | 4 | 1 |
View Market Depth
| Last trade - 11.54am 18/06/2025 (20 minute delay) ? |
| CSL (ASX) Chart |